Position in ELVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$6,421,955
+$6,421,955 QoQ
Shares Held
126,541
Ownership
0.173%
of shares outstanding
% of Portfolio
1.04%
of 13F equity value
Holder Rank
#71
of 210 holders
Holding Since
Jun 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ELVN Over Time
Shares Held
Position Value (USD)
Derivatives in ELVN
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$3,281,040
PutShares
83,700
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Ikarian Capital, LLC holds $559,861,982 across 103 Biotechnology names. ELVN ranks #28 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
328,635 | $43,793,900 | |
| 2 | KOD |
Kodiak Sciences Inc.
|
1,059,730 | $41,287,080 | |
| 3 | ALMS |
Alumis Inc.
|
870,548 | $24,497,220 | |
| 4 | PRAX |
Praxis Precision Medicines, Inc.
|
72,842 | $24,386,773 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
388,682 | $22,594,084 | |
| 6 | CLDX |
Celldex Therapeutics, Inc.
|
478,500 | $17,804,985 | |
| 7 | RCUS |
Arcus Biosciences, Inc.
|
504,559 | $15,555,553 | |
| 8 | RLMD |
Relmada Therapeutics, Inc.
|
2,148,359 | $14,866,644 |
All Filings in ELVN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,421,955 | 126,541 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $3,281,040 | 83,700 | Put | Sole | 2026-05-15 | |
| 2025-03-31 | $5,698,107 | 289,538 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $8,877,105 | 394,538 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $12,758,915 | 499,566 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $13,707,720 | 586,552 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||